April 13, 2020 -- ThermoGenesis has announced that its joint venture, ImmuneCyte Life Sciences, has acquired intellectual property for developing antibody therapeutics for COVID-19.
The intellectual property ImmuneCyte has purchased includes four monoclonal antibody drug candidates against SARS-CoV-2, which were obtained from B cell samples from patients who recovered from the disease. The drug candidates were initially developed by researchers at East China Normal University in Shanghai.
ThermoGenesis is also developing a treatment called convalescent plasma therapy that gives patients a plasma infusion from people who have recovered from COVID-19 using its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection kit, it said.
Copyright © 2020 scienceboard.net